To further confirm that AKT pathway was targeted by brassicasterol in HCC inhibition, PLC5 and HepG2.215 cells were treated with brassicasterol in the presence or absence of AKT agonist. This evidence concerns the gene AKT1 and hepatocellular carcinoma.